National e-Conference on Drug Discovery for CNS Disorders

Date: 6 – 10 December 2021 | Online platform


  • Scope: Ensure that the field of your study/abstract is in the broad field of Drug discovery/ Pharmacology/ Translational research/ Clinical drug development and involves your original research, case studies or metanalysis etc.

  • Abstract title: The title is limited to 180 characters including spaces and should be brief and relevant. Special characters should NOT be used in the title, instead spell it out (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.

  • Authors: All authors should be associated with the work done in some manner. Number of authors is limited to 10. Presenting author must be underlined. All affiliations must be listed in the abstract. A registered delegate shall present only one research presentation.

  • Abstract body: The abstract should be structured and laid out under the headings- Background, Aims, Method, Results and Discussion.

  • Font size and style: Times New Roman font must be used with font size of 18 for title, 14 for sub-headers and 12 for body of the text, with spacing of 1.5 points. The length of the abstract is limited to 500 words only.

  • Only commonly accepted abbreviations should be used. Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM). Only approved and generic (non-proprietary) drug names should be used. Do NOT include the title, authors, or grant information in the abstract body.

  • Abstract submission format: The abstract must be prepared in PDF/WORD (docx) format. Send the file as an attachment to on or before 10 November 2021. Abstracts will not be accepted after the deadline. The subject of the mail should include the following: “Abstract submission – CNS conference”

  • Selection: All submitted abstracts undergo a review process. Accepted abstracts will be selected for research presentations. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the conference Committee is final and irrevocable.

  • Notification: Acceptance or rejection of submitted abstracts will be intimated to the submitting author by 17 November 2021. It is the responsibility of the submitting author to inform all other authors of the submission and status of the abstract and request their registration for the conference.

  • Author Registration: Presenting authors of the accepted abstracts MUST register for the conference by 30 November 2021. If registration fee (including the GST) is not paid by the deadline, the abstract will be withdrawn. Abstracts selected for presentation will be published in a suitable journal.

  • Originality, plagiarism, ethical approval, copyright: It is the responsibility of the authors to ensure originality of the research, as well as the abstract and posters. All authors are requested to adhere to publication ethics and ensure no conflicts are present with regards to submission of abstracts. It is the responsibility of the authors to ensure appropriate ethical/regulatory approval has been taken where applicable for the images/data/research material which is presented/published via this conference.

  • Presentation details: Instructions about the presentation will be intimated in November after completion of the selection process.

  • Any clarifications or communication regarding abstracts should be directed to with the subject of the mail being: “Query – CNS conference”